{"filing":{"accession_number":"0001193125-26-248289","cik":"0001808898","ticker":"BNTC","company_name":"Benitec Biopharma Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"bntc-20260522.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/bntc-20260522.htm"},"events":[{"id":8121,"run_id":7128,"accession_number":"0001193125-26-248289","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the appointment of David Friedman as a Class III director effective May 22, 2026, which is the principal action. While the section also mentions Megan Boston's resignation from the Board (though she remains CFO and secretary), the appointment is the affirmative governance action that drives the disclosure. The grant of 35,000 stock options is ancillary compensation tied to the appointment. Board composition changes are material to investors assessing corporate governance.","company_name":"Benitec Biopharma Inc.","ticker":"BNTC","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2717,"accession_number":"0001193125-26-248289","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of David Friedman as a Class III director effective May 22, 2026, which is the principal action. While the section also mentions Megan Boston's resignation from the Board (though she remains CFO and secretary), the appointment is the affirmative governance action that drives the disclosure. The grant of 35,000 stock options is ancillary compensation tied to the appointment. Board composition changes are material to investors assessing corporate governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:42.776828+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2717,"accession_number":"0001193125-26-248289","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of David Friedman as a Class III director effective May 22, 2026, which is the principal action. While the section also mentions Megan Boston's resignation from the Board (though she remains CFO and secretary), the appointment is the affirmative governance action that drives the disclosure. The grant of 35,000 stock options is ancillary compensation tied to the appointment. Board composition changes are material to investors assessing corporate governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:42.776828+00:00","company_name":"Benitec Biopharma Inc.","ticker":"BNTC","filing_date":"2026-05-29"}]}